EUVIMEDEUVIMED entdecken
Crossref

Incidence and Management of Posttransplantation Lymphoproliferative Disorder After Pediatric Solid Organ Transplantation: The Norwegian Experience

Olav Sondre Skorge Aartun iD, Karen Henriette Hustveit iD, Monica Cheng Munthe-Kaas iD, Ann Christin Gjerstad iD, Anna Bjerre, Anniken Bjørnstad Østensen iD, Thomas Möller iD

Pediatric Transplantation · 2025

DOI: 10.1111/petr.70040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2025. Verfasst von Olav Sondre Skorge Aartun und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric and Adolescent Medicine, Department of Transplantation and Specialized Pediatrics, Oslo University Hospital, Oslo, Norway. Hauptthemen laut MEDLINE: Lymphoproliferative Disorders, Organ Transplantation, Postoperative Complications. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Oslo University Hospital, Oslo universitetssykehus HF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Posttransplant lymphoproliferative disorder (PTLD) is a complication of solid organ transplantation (SOT) due to immunosuppression. In 2023, a pediatric PTLD register was established in Norway because of a perceived increase in the incidence of pediatric PTLD. This study aimed to analyze population‐based data on the incidence and management of pediatric PTLD after SOT using the pediatric PTLD registry in Norway.

Methods

This retrospective quality assurance study collected the data of pediatric patients with PTLD after SOT in Norway from January 1, 1995, to December 31, 2023. For comparison and calculation of incidence rates, SOT patients without PTLD required a minimum of 1 year posttransplant follow‐up to be included.

Results

A total of 457 patients underwent SOT (57% males) and 22 (4.8%) developed PTLD (73% males). The median age at transplant in the SOT and PTLD groups were 9.5 (interquartile range, 2.4–14.5) and 4.3 (1.1–12.5) years, respectively. Twenty patients with PTLD (91%) were Epstein–Barr virus naive at the time of transplantation. Eighteen (82%) and four (18%) patients developed early and late PTLD, respectively. Ten patients had monomorphic PTLD (45%). All patients received a reduction in immunosuppression, 15 received rituximab, and six required chemotherapy. Six patients (27%) died after PTLD, five of whom had active PTLD disease at the time of death. None of the patients experienced graft loss.

Conclusions

Our findings regarding the incidence, EBV status, sex, and age at transplantation align with those of previous studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoproliferative DisordersOrgan TransplantationPostoperative ComplicationsHumansMaleFemaleNorwayChildIncidenceRetrospective StudiesChild, PreschoolAdolescentInfantRegistriesImmunosuppressive AgentsFollow-Up Studies

Stichwörter der Autor:innen

Epstein–Barr virusheart transplantkidney transplantliver transplantpediatric transplantposttransplant lymphoproliferative diseasereduction of immunosuppressionsolid organ transplant

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Division of Pediatric and Adolescent Medicine, Department of Transplantation and Specialized Pediatrics, Oslo University Hospital, Oslo, Norway.
  • Division of Pediatric and Adolescent Medicine, Department of Pediatric Oncology and Hematology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Division of Pediatric and Adolescent Medicine, Department of Pediatric Cardiology, Oslo University Hospital, Oslo, Norway.

ORCID-Profile: Olav Sondre Skorge Aartun, Karen Henriette Hustveit, Monica Cheng Munthe-Kaas, Ann Christin Gjerstad, Anniken Bjørnstad Østensen, Thomas Möller

Förderung

  • Oslo University Hospital
  • Oslo universitetssykehus HF

Zitieren

APA

Aartun, O. S. S., Hustveit, K. H., Munthe-Kaas, M. C., Gjerstad, A. C., Bjerre, A., Østensen, A. B., & Möller, T. (2025). Incidence and Management of Posttransplantation Lymphoproliferative Disorder After Pediatric Solid Organ Transplantation: The Norwegian Experience. Pediatric Transplantation. https://doi.org/10.1111/petr.70040

Vancouver

Aartun OSS, Hustveit KH, Munthe-Kaas MC, Gjerstad AC, Bjerre A, Østensen AB, et al. Incidence and Management of Posttransplantation Lymphoproliferative Disorder After Pediatric Solid Organ Transplantation: The Norwegian Experience. Pediatric Transplantation. 2025. doi:10.1111/petr.70040

BibTeX
@article{Aartun2025,
  author = {Aartun, Olav Sondre Skorge and Hustveit, Karen Henriette and Munthe-Kaas, Monica Cheng and Gjerstad, Ann Christin and Bjerre, Anna and Østensen, Anniken Bjørnstad and Möller, Thomas},
  title = {Incidence and Management of Posttransplantation Lymphoproliferative Disorder After Pediatric Solid Organ Transplantation: The Norwegian Experience},
  journal = {Pediatric Transplantation},
  year = {2025},
  doi = {10.1111/petr.70040}
}
Kostenlos starten →